Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm
1989816 citationsKenneth D. Paull, Robert H. Shoemaker et al.JNCI Journal of the National Cancer Instituteprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
Countries citing papers authored by Jacqueline Plowman
Since
Specialization
Citations
This map shows the geographic impact of Jacqueline Plowman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline Plowman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline Plowman more than expected).
Fields of papers citing papers by Jacqueline Plowman
This network shows the impact of papers produced by Jacqueline Plowman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline Plowman. The network helps show where Jacqueline Plowman may publish in the future.
Co-authorship network of co-authors of Jacqueline Plowman
This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline Plowman.
A scholar is included among the top collaborators of Jacqueline Plowman based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Jacqueline Plowman. Jacqueline Plowman is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Plowman, Jacqueline, Donald J. Dykes, V. L. Narayanan, et al.. (1995). Efficacy of the quinocarmycins KW2152 and DX-52-1 against human melanoma lines growing in culture kand in mice.. PubMed. 55(4). 862–7.20 indexed citations
Zaharko, Daniel S., et al.. (1992). L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.. PubMed. 52(13). 3604–9.1 indexed citations
Paull, Kenneth D., Robert H. Shoemaker, Louis Hodes, et al.. (1989). Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm. JNCI Journal of the National Cancer Institute. 81(14). 1088–1092.816 indexed citations breakdown →
9.
Paull, Kenneth D., et al.. (1988). Reproducibility and response patterns of the ic50 values and relative cell line sensitivities from the nci human tumor cell line drug screening project. 29. 488.3 indexed citations
10.
O’Dwyer, Peter J., Susan A. King, Jacqueline Plowman, et al.. (1988). Pyrazole: preclinical reassessment. Investigational New Drugs. 6(4). 305–310.10 indexed citations
Dalal, Maha, Jacqueline Plowman, Theodore R. Breitman, et al.. (1986). Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties.. PubMed. 46(2). 831–8.24 indexed citations
16.
Plowman, Jacqueline, et al.. (1986). Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.. PubMed. 70(12). 1415–21.43 indexed citations
17.
Hoth, Daniel F., Matthew Suffness, Jacqueline Plowman, et al.. (1986). Didemnin B. Investigational New Drugs. 4(3). 279–284.71 indexed citations
Dexter, Daniel L., David P. Hesson, Robert Ardecky, et al.. (1985). Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.. PubMed. 45(11 Pt 1). 5563–8.80 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.